Ghent University Academic Bibliography

Your filters: cql: author="Molenaar, Jan" or (type any "bookEditor issueEditor" and editor="Molenaar, Jan")

Add to list
- Journal Article
- A1
- open access
Targeted AURKA degradation : towards new therapeutic agents for neuroblastoma

Muhammad Rishfi (UGent) , Simon Krols (UGent) , Fien Martens (UGent) , Sarah-Lee Bekaert (UGent) , Ellen Sanders (UGent) , Aline Eggermont (UGent) , Fanny De Vloed (UGent) , Joshua Robert Goulding (UGent) , Martijn Risseeuw (UGent) , Jan Molenaar, et al.

(2023) EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. 247.
Add to list
- Conference Paper
- C3
RRM2 enhances MYCN driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition

Lisa Depestel (UGent) , Carolina de Carvalho Nunes, Liselot Mus (UGent) , Iris Nelen (UGent) , Louis Delhaye (UGent) , Kaylee Keller, Volodimir Olexiouk, Fanny De Vloed (UGent) , Ellen Sanders (UGent) , Aline Eggermont (UGent) , et al.

(2022) OncoPoint Symposium, 8th, Abstracts.
Add to list
- Journal Article
- A1
- open access
RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition

Carolina de Carvalho Nunes, Lisa Depestel (UGent) , Liselot Mus (UGent) , Kaylee M. Keller, Louis Delhaye (UGent) , Amber Louwagie (UGent) , Muhammad Rishfi (UGent) , Alex Whale, Neesha Kara, Simon R. Andrews, et al.

(2022) SCIENCE ADVANCES. 8(28).
Add to list
Accelerating drug development for neuroblastoma : summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma

Lucas Moreno, Giuseppe Barone, Steven G. DuBois, Jan Molenaar, Matthias Fischer, Johannes Schulte, Angelika Eggert, Gudrun Schleiermacher, Franki Speleman (UGent) , Louis Chesler, et al.

(2020) EUROPEAN JOURNAL OF CANCER. 136. p.52-68
Add to list
- Conference Paper
- C3
The RRM2-PHF6 complex protects neuroblastoma cells from DNA damage accumulation to install a replication stress resistance phenotype

Carolina de Carvalho Nunes, Kaat Durinck (UGent) , Lisa Depestel (UGent) , Siebe Loontiens (UGent) , Louis Delhaye (UGent) , Sofia Zanotti, Emmy Dolman, Aline Eggermont (UGent) , Bieke Decaesteker (UGent) , Pauline Depuydt, et al.

(2018) Advances in Neuroblastoma Research, Congress abstracts.
Add to list
- Conference Paper
- C3
HBP1 is a negative epigenetic regulator of MYCN-driven neuroblastoma through interaction with the PRC2 complex

Shana Claeys (UGent) , Geertrui Denecker (UGent) , Irina Lambertz (UGent) , Els Janssens (UGent) , Suzanne Vanhauwaert (UGent) , Bieke Decaesteker (UGent) , Tom Van Maerken (UGent) , Bram De Wilde (UGent) , Genevieve Laureys (UGent) , Kristina Althoff, et al.

(2017) Treatment and Research Center for Pediatric Oncology and Haematology Heidelberg, Opening symposium, Abstracts.
Add to list
Accelerating drug development for neuroblastoma - New drug development strategy : an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project

Lucas Moreno, Hubert Caron, Birgit Geoerger, Angelika Eggert, Gudrun Schleiermacher, Penelope Brock, Dominique Valteau-Couanet, Louis Chesler, Johannes Schulte, Katleen De Preter (UGent) , et al.

(2017) EXPERT OPINION ON DRUG DISCOVERY. 12(8). p.801-811
Add to list
- Conference Paper
- C3
The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex

Shana Claeys (UGent) , Irina Lambertz (UGent) , Els Janssens (UGent) , Suzanne Vanhauwaert (UGent) , Bieke Decaesteker (UGent) , Candy Kumps (UGent) , Sara De Brouwer (UGent) , Annelies Fieuw (UGent) , Tom Van Maerken (UGent) , Bram De Wilde (UGent) , et al.

(2016) OncoPoint, 4th Research seminar, Abstracts.
Add to list
- Conference Paper
- C3
The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex

Shana Claeys (UGent) , Irina Lambertz (UGent) , Els Janssens (UGent) , Suzanne Vanhauwaert (UGent) , Bieke Decaesteker (UGent) , Candy Kumps (UGent) , Sara De Brouwer (UGent) , Annelies Fieuw (UGent) , Tom Van Maerken (UGent) , Bram De Wilde (UGent) , et al.

(2016) Advances in Neuroblastoma Research, Congress abstracts.

Academic Bibliography

Targeted AURKA degradation : towards new therapeutic agents for neuroblastoma

RRM2 enhances MYCN driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition

RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition

Accelerating drug development for neuroblastoma : summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma

The RRM2-PHF6 complex protects neuroblastoma cells from DNA damage accumulation to install a replication stress resistance phenotype

HBP1 is a negative epigenetic regulator of MYCN-driven neuroblastoma through interaction with the PRC2 complex

Accelerating drug development for neuroblastoma - New drug development strategy : an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project

The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex

The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex

Contents

Support

Contact